by COR2ED Medical Education
Join obstetrics and gynecology specialists as they discuss their approaches to diagnosing, treating and supporting women in a range of clinical situations. The conversations explore optimising maternal outcomes, managing severe PHH, and best practices for OBGYN procedures. This independent medical education podcast is for HCPs with the ultimate goal of improving care for their patients. For more information, visit www.cor2ed.com
Language
🇺🇲
Publishing Since
12/6/2023
Email Addresses
1 available
Phone Numbers
0 available
February 17, 2025
Advanced or recurrent endometrial cancer: Molecular classification and treatment decisions Key clinical takeaways: MMR status should be tested in all patients at diagnosis and upon disease progression to guide personalised treatment decisions ICI and ChT combination, including with maintenance olaparib, demonstrates benefits in patients with non-dMMR advanced/recurrent endometrial cancer, with greater efficacy observed in dMMR populations Lenvatinib plus pembrolizumab is a viable option not only as 2nd line therapy but also as 1st line treatment for patients with non-dMMR advanced/recurrent endometrial cancer who have progressed after prior systemic therapy in any setting Shared decision-making, supported by patient education, is essential for optimising treatment outcomes The treatment landscape for advanced and recurrent endometrial cancer (EC) is evolving, with molecular classification playing a key role in guiding decisions. In this podcast, Prof. Xavier Matias-Guiu (Pathologist) and Dr Jurjees Hasan (Medical Oncologist) discuss the latest advancements in personalised treatment approaches for EC. Key topics include: The role of molecular classification in guiding treatment selection and testing strategies Treatment options for patients with pMMR status Effective patient communication for shared decision-making Tune in for expert insights and practical guidance to optimise treatment strategies in advanced and recurrent EC You can also watch a video of the experts in conversation and download the accompanying transcript on our website: https://cor2ed.com/obstetrics-gynecology-connect/programmes/endometrial-cancer-molecular-classification-treatment-decisions/ Or watch on YouTube: https://youtu.be/KvYIB7PBpyQ Follow us on social media: LinkedIn: https://www.linkedin.com/company/ob-gyn-connect/?viewAsMember=true X: https://x.com/OBGynConnect This content is intended for healthcare professionals only. The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This programme has been sponsored by Eisai Europe Limited ("Eisai"). Eisai has had no input on the educational content of, or speakers involved in this podcast. This podcast is developed by cor2ed.com Published February 2025 Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.
January 13, 2025
Prof. Loïc Sentilhes and Prof. Christian von Heymann, experts in obstetrics and gynecology, discuss the latest strategies for preventing and managing postpartum hemorrhage, emphasizing the importance of prompt diagnosis and evidence-based treatment.
June 17, 2024
<p>COR2ED Medical Education: In this podcast, Prof. Andra H. James (Professor Emeritus of Obstetrics and Gynecology, Division Maternal Fetal Medicine, Duke University Hospital, Durham, North Carolina, US) and Dr Maria Elisa Mancuso (Senior Haematology Consultant at the Center for Thrombosis and Hemorrhagic Diseases of IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy) discuss various treatment options for severe postpartum haemorrhage (also called PPH).</p> <p>Experts discuss what causes PPH and how to determine the risk before and during labour with algorithms and other helpful tools. The discussion moves to when haematologic expertise is required and how collaboration can be optimized to provide the best care for patients. Furthermore, the experts share their learnings from clinical practice through discussion of specific patient cases, including patients with and without underlying bleeding disorders, as well as where haemostatic agents fit in the protocol.</p>
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at [email protected] for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.
